Acta Endocrinologica-Bucharest is a vital resource for those engaged in the study and practice of endocrinology, diabetes, and metabolic research. Published by EDITURA ACAD ROMANE, this journal emphasizes the dissemination of high-quality research and insights specific to the fields of endocrinology and autonomic systems. Although categorized in the lower quartiles of its subject areas according to the latest rankings—Q4 in Endocrine and Autonomic Systems and Q4 in Endocrinology—it serves as an important platform for emerging scientific ideas and collaborative studies within the endocrinology community. With an ISSN of 1841-0987 and an E-ISSN of 1843-066X, the journal provides a significant opportunity for authors to contribute to the growing body of knowledge in these fields from its base in Romania. Researchers and practitioners alike will find valuable contributions that reflect both contemporary challenges and advances in endocrinology, reinforcing the journal's commitment to enhancing scholarly communication.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

Revista Portuguesa de Endocrinologia Diabetes e Metabolismo is a pivotal journal dedicated to advancing the fields of endocrinology, diabetes, and metabolism. Published by the esteemed SOC PORTUGUESA ENDOCRINOLOGIA, DIABETES & METABOLISMO-SPEDM, this journal serves as a platform for the dissemination of high-quality research, clinical studies, and innovative practices within these related disciplines. With a commitment to providing insightful and impactful content, the journal aims to foster knowledge sharing among researchers, healthcare professionals, and students interested in the latest developments in endocrine disorders and metabolic diseases. Although currently not open access, the journal's comprehensive approach and rigorous peer-review process ensure that it remains a respected source of information for its readers in Portugal and beyond. With its address rooted in the heart of Lisbon, the Revista Portuguesa de Endocrinologia Diabetes e Metabolismo plays a vital role in enhancing the understanding and treatment of endocrine and metabolic conditions in the modern healthcare landscape.

Endocrinology Diabetes and Metabolism Case Reports, published by BIOSCIENTIFICA LTD, stands as a pivotal forum for sharing significant advancements and clinical case studies in the fields of endocrinology, diabetes, and metabolism. With an Open Access model initiated in 2013, this journal encourages the widespread dissemination and accessibility of research findings, promoting collaboration and innovation among scholars and healthcare professionals. Based in the United Kingdom, the journal features a focus on practical applications and unique case reporting that enriches the clinical understanding and management of complex endocrine disorders. Though currently it's ranked in the Q3 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, its ongoing commitment to quality and impact in clinical research makes it a valuable resource for researchers, professionals, and students alike, contributing to the advancement of knowledge in this critical medical domain.

JOURNAL OF ENDOCRINOLOGY, established in 1946 and published by BIOSCIENTIFICA LTD, stands as a premier scholarly outlet in the field of endocrinology, diabetes, and metabolism. With an impressive H-Index reflecting its significant contribution to the literature, this journal maintains a strong presence in academic circles, evidenced by its Q1 ranking in the 2023 Scopus categories for both Endocrinology and Diabetes and Metabolism. With its targeted scope serving a global audience of researchers, professionals, and students, it provides a vital platform for disseminating innovative research findings and advancing the scientific understanding of endocrine systems. As we approach its convergence year of 2024, JOURNAL OF ENDOCRINOLOGY remains committed to publishing high-quality, peer-reviewed articles that explore cutting-edge developments in the field, thereby impacting clinical practices and guiding future research directions.

BMC Endocrine Disorders is a leading open-access journal dedicated to advancing the field of endocrinology, diabetes, and metabolism. Published by BMC since 2001, this journal provides a vibrant platform for researchers to disseminate their findings across a wide array of topics related to endocrine health and disorders. With an impressive Q2 category ranking in both Endocrinology, Diabetes and Metabolism, and Medicine (miscellaneous) for 2023, it has positioned itself among the top-tier journals in its field, reflecting its commitment to high-quality research and discussions. The journal's accessibility enhances its reach and impact, ensuring that important findings are available to all stakeholders in the medical community. Researchers, healthcare professionals, and students alike will find valuable insights and updates that are crucial for both academic and practical applications within this dynamic field. The journal is actively welcoming submissions through 2024, facilitating continuous growth in the scientific discourse surrounding endocrine disorders.

CYTOKINE is a prestigious peer-reviewed journal published by Academic Press Ltd - Elsevier Science Ltd, dedicated to advancing the field of immunology, biochemistry, and related biomedical sciences since its inception in 1989. With an ISSN of 1043-4666 and an E-ISSN of 1096-0023, this journal serves as a vital resource for researchers and professionals alike, offering cutting-edge research findings that delve into the roles and mechanisms of cytokines in health and disease. Recognized for its impactful contributions, CYTOKINE currently ranks in the Q2 quartile across several categories, including Biochemistry, Hematology, and Immunology, indicating its significant influence in these fields. Despite not offering open access, the journal maintains a high-quality standard, as evidenced by its robust Scopus rankings, including a notable 80th percentile in Medicine and Hematology. Researchers and students are encouraged to explore the latest findings and methodologies via CYTOKINE, as it continues to shape the future landscape of cytokine research and application.

ENDOCRINE JOURNAL, published by the Japan Endocrine Society, is a pivotal resource for researchers and professionals in the field of endocrinology, diabetes, and metabolism. With a long history dating back to 1954, this journal encompasses a comprehensive range of topics including hormonal regulation, pathophysiology of endocrine diseases, and innovative therapeutic approaches. Despite its classification as open access, the journal remains a beacon of knowledge, with impressive rankings—Q2 in Endocrinology, Diabetes and Metabolism and Q3 in Endocrinology for 2023—ensuring it is a respected source in the academic community. It serves as a critical platform for the dissemination of cutting-edge research, encouraging collaboration and facilitating advancements in understanding complex endocrine disorders. By subscribing to this journal, researchers and students gain access to seminal studies, clinical insights, and a wealth of information that drives this vital field forward.

Immunity, Inflammation and Disease is a premier open-access journal published by WILEY, dedicated to advancing the field of immunology and allergy. Launched in 2013, this journal has established itself as a significant platform for researchers and professionals to disseminate high-quality research findings and innovative insights that address critical issues in immune responses and inflammatory diseases. With an impact factor that reflects its growing influence and a current ranking in Q3 for Immunology and Q2 for Immunology and Allergy, this journal serves a diverse audience keen on exploring cutting-edge developments. Researchers are encouraged to submit their work to share their findings with a global reach, foster collaboration, and enhance the understanding of immune mechanisms and therapeutic strategies. Accessible since its inception, Immunity, Inflammation and Disease is committed to open science, ensuring that vital research is freely available for the advancement of knowledge within the academic community and beyond.

Journal of the Endocrine Society, published by the ENDOCRINE SOC, stands as a prominent platform for disseminating significant research and findings within the field of endocrinology, diabetes, and metabolism. Established as an Open Access journal since 2017, it aims to increase the visibility and accessibility of vital scholarly contributions, allowing researchers and professionals from various backgrounds to engage with the latest insights in this rapidly evolving discipline. With an impressive Q2 ranking in Endocrinology, Diabetes and Metabolism, the journal is recognized for its impact, ranking #100 out of 244 in Scopus, highlighting its role in advancing scientific knowledge and fostering innovation. The journal, based in the United States at 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036, continues to enrich the academic landscape by converging state-of-the-art research and clinical applications through its publication cycle from 2017 to 2024. Researchers, students, and healthcare professionals are encouraged to explore this essential resource to stay at the forefront of endocrinological advancements.